title: Will the promise of drug-induced therapeutic hypothermia be fulfilled?
authors.affiliation: Department of Neurology, Department of Anesthesia and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD Department of Neurology, Department of Anesthesia and Critical Care Medicine, Department of Neurosurgery, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Mulder
authors.forename: Romergryko G
authors.initials: RG
authors.lastname: Geocadin
mesh_terms: D000818:Animals; D048588:Benzoxazines / Q000627:therapeutic use*; D001921:Brain / Q000503:physiopathology*; D063386:Cannabinoid Receptor Agonists / Q000627:therapeutic use*; D016887:Cardiopulmonary Resuscitation / Q000379:methods*; D006321:Heart / Q000503:physiopathology*; D006323:Heart Arrest / Q000188:drug therapy*; D007036:Hypothermia, Induced / Q000379:methods*; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D009281:Naphthalenes / Q000627:therapeutic use*
chemical_list: D048588:Benzoxazines; D063386:Cannabinoid Receptor Agonists; D009025:Morpholines; D009281:Naphthalenes; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone